Al Daama S.A.,King Fahad Speciality Hospital Dammam |
Aldayel A.Q.,King Fahad Speciality Hospital Dammam |
Alafgani S.,King Fahad Speciality Hospital Dammam |
Abolela M.,King Fahad Speciality Hospital Dammam |
And 4 more authors.
Life Science Journal | Year: 2013
Acute myeloid leukemia (AML) is a heterogeneous disease that accounts for approximately 20% of acute leukemias in children and adolescents. Despite the lack of targeted therapy for most subtypes, survival rates have reached approximately 60% for children treated on clinical trials in developed countries. Most of the advances have been accomplished by better risk classification, the implementation of excellent supportive care measures, adaptation of therapy on the basis of each patient's response to therapy, and improvements in allogeneic hematopoietic stem cell transplantation (HST). However, it is unlikely that further gains can be made through these measures alone. The identification of molecular abnormalities that are potential targets of new therapies is expected to pose much impact on the treatment outcomes of the disease. The development of molecularly targeted agents holds great promise for the future as well. The present study reports the King Fahd Specialist Hospital-Dammam (KFSH-D) experience in the management of pediatric AML patients who referred to the hemato-oncology department starting from May 2008 until September 2012 as well as the result of their follow up.